MedTrace Logo

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

NCT06350487 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2024-04-08

No results posted yet for this study

Summary

The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF).

Conditions

  • Heart Failure, Preserved Ejection Fraction

Interventions

DRUG

SGLT2 inhibitor

Enavogliflozin (0.3mg oral tablet once daily) will be administrated.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jeong Hoon Yang, MD, PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06350487 on ClinicalTrials.gov